TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- SciSparc Ltd.
(NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company
focusing on the development of therapies to treat disorders of the
central nervous system (the "Company" or "SciSparc"), marks today
one of the Company's most important milestones to date - the U.S.
Patent and Trademark Office has granted it a new patent - U.S.
Patent No. 11,207,290, titled combinations of cannabinoids and
n-acylethanolamines (the "Patent"). The invention relates to
"Pharmaceutical compositions comprising cannabinoids and
N-acylethanolamines, and methods for their use in preventing and
treating a variety of cannabinoid-treatable conditions."
"As an innovative pharmaceutical company, our IP portfolio is
one of our greatest and most important assets. Obtaining a U.S.
patent for our core technology constitutes a major achievement for
us, especially as we are one of the few companies in the field that
has IP protection on compounds and not only indications. We are
pleased that the U.S. Patent and Trademark Office has again
recognized the uniqueness of our compounds and methodologies and
granted this patent," said Adi Zuloff-Shani, PhD, Chief
Technologies Officer of SciSparc.
This patent further strengthens the Company's intellectual
property portfolio and protection of its core technologies, and in
one of the most important markets in the world.
This is SciSparc's fourth granted patent in the U.S. Recently,
the Company announced it has been granted the same patent in
Australia and Japan.
Dr. Zuloff-Shani added, "Our growing portfolio of patents is a
testament to the dedication and innovation of the SciSparc team and
strengthens our commitment to continue the work we do to bring
therapies to patients suffering with the challenges associated with
disorders of the central nervous system, for whom there is
currently no effective treatment."
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. Our focus is on creating and enhancing a portfolio of
technologies and assets based on cannabinoid pharmaceuticals. With
this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive
cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome
and for the treatment of obstructive sleep apnea; SCI-160 for the
treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and epilepsy.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other U.S. federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses its potential to bring therapies to
patients suffering with the challenges associated with disorders of
the central nervous system. Because such statements deal with
future events and are based on SciSparc's current expectations,
they are subject to various risks and uncertainties and actual
results, performance or achievements of SciSparc could differ
materially from those described in or implied by the statements in
this press release. The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading "Risk
Factors" in SciSparc's Annual Report on Form 20-F filed with the
U.S. Securities and Exchange Commission (the "SEC") on
March 30, 2021, and in subsequent
filings with the SEC. Except as otherwise required by law, SciSparc
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scisparc-issued-us-patent-for-its-core-technology-that-treats-central-nervous-systems-disorders-301453525.html
SOURCE SciSparc Ltd.